Reduced bone mineral density (BMD) and an increased risk of vertebral fracture have been reported in calcium-stone-forming (CSF) patients presenting with idiopathic hypercalciuria. We investigated the association between Bsm I vitamin D receptor (VDR) polymorphism and BMD in 68 hypercalciuric CSF patients (35 males and 33 premenopausal females, mean age ± SD = 39 ± 10 years). BMD was measured at lumbar spine (L2–L4) and femur neck sites using dual energy X-ray absorptiometry. A 72-hour dietary record and a 24-hour urine sample were obtained from each patient to determine calcium intake and excretion. The allelic frequency found for the sample as a whole was 16% BB, 44% Bb and 40% bb. Mean BMD values did not significantly differ among BB, Bb and bb patients at L2–L4 (1.162 ± 0.10, 1.133 ± 0.11 and 1.194 ± 0.19 g/cm2, mean ± SD, respectively) or at neck sites (0.920 ± 0.11, 0.931 ± 0.15 and 0.982 ± 0.15 g/cm2, respectively). Calcium intake and excretion were also not significantly different among the three genotypes. Patients were then divided into two groups, normal BMD, T-score ≧–1 (n = 34) and low BMD, T-score <–1 (n = 34), to further evaluate the allele influence on previous bone loss. Despite a trend for a higher mean BMD at spine or neck sites for patients with one or two b alleles when compared to BB patients, the difference did not reach statistical significance. The distribution of BB, Bb and bb genotypes in the low-bone-mass group (15, 47 and 38%, respectively) was similar to that in the normal-bone-mass group (18, 41 and 14%, respectively). These data suggest that Bsm I VDR polymorphism does not play an important role in the bone loss seen in hypercalciuric CSF patients.

Keywords:
Hypercalciuria, Nephrolithiasis, Osteopenia, Bone mineral density, Vitamin D receptor polymorphism
1.
Coe FL, Parks J; Asplin JR: The pathogenesis and treatment of kidney stones. N Engl J Med 1992;327:1141–1151.
2.
Pak CYC: Etiology and treatment of urolithiasis. Am J Kidney Dis 1991;18:624–637.
3.
Lemann J Jr, Worcester EM, Gray RW: Hypercalciuria and stones. Am J Kidney Dis 1991;17:386–391.
4.
Brannon PG, Morawski S, Pak CYC, Fordtran J: Selective jejunal hyperabsorption of calcium in absorptive hypercalciuria. Am J Med 1979;66:425–428.
5.
Breslau NA, Preminger GM, Adams BY, Otey J, Pak CYC: Use of ketoconazole to probe the pathogenetic importance of 1,25 dihydroxyvitamin D in absorptive hypercalciuria. J Clin Endocrinol Metab 1992;75:1446–1452.
6.
Tsuruoka S, Bushinsky DA, Schwartz GJ: Defective renal calcium reabsorption in genetic hypercalciuric rats. Kidney Int 1997;51:1540–1457.
7.
Bushinsky DA, Neumann KJ, Asplin J, Krieger NS: Alendronate decreases urine calcium and supersaturation in genetic hypercalciuric rats. Kidney Int 1999;55:234–243.
8.
Li XQ, Tembe V, Horwitz GM, Bushinsky DA, Favus MJ: Increased intestinal vitamin D receptor in genetic hypercalciuric rats. J Clin Invest 1993;91:661–667.
9.
Krieger NS, Stathopoulos VM, Bushinsky DA: Increased sensitivity to 1,25(OH)2D3 in bone from genetic hypercalciuric rats. Am J Physiol 1996;271:C130–C135.
10.
Heilberg IP, Martini LA, Szejnfeld VL, Carvalho AB, Draibe SA, Ajzen H, Ramos OL, Schor N: Bone disease in calcium stone-forming patients. Clin Nephrol 1994;42:175–182.
11.
Bataille P, Achard JM, Fournier A, Boudailliez B, Westeel PF, Esper NE, Bergot C, Jans I, Lalau JD, Petit J, Henon G, Jeantet MAL, Bouillon R, Sebert JI: Diet, vitamin D and vertebral mineral density in hypercalciuric calcium stone formers. Kidney Int 1991;39:1193–1205.
12.
Jaeger P, Lippuner K, Casez JP, Hess B, Ackermann D, Hug C: Low bone mass in idiopathic renal stone formers: Magnitude and significance. J Bone Miner Res 1994;9:1525–1532.
13.
Lawoyin S, Sismilich S, Browne R, Pak CYC: Bone mineral content in patients with calcium urolithiasis. Metabolism 1979;28:1250–1254.
14.
Ghazali A, Fuentès V, Desaint C, Bataille P, Westeel A, Brazier M, Prin L, Fournier A: Low bone mineral density and peripheral blood monocyte activation profile in calcium stone formers with idiopathic hypercalciuria. J Clin Endocrinol Metab 1997;82:32–38.
15.
Weisinger JR: New insights into the pathogenesis of idiopathic hypercalciuria: The role of bone. Kidney Int 1996;49:1507–1518.
16.
Heilberg IP, Martini LA, Teixeira SH, Szejnfeld VL, Carvalho AB, Lobao R, Draibe SA: Effect of etidronate treatment on bone mass of male nephrolithiasis patients with idiopathic hypercalciuria and osteopenia. Nephron 1998;79:430–437.
17.
Malluche HH, Tschoepe W, Rits E, Meyer-Sebellek W, Massry S: Abnormal bone histology in idiopathic hypercalciuria. J Clin Endocrinol Metab 1980;50:654.
18.
Steiniche T, Moselkide L, Christensen MS, Melsen F: A histomorphometric determination of iliac bone remodeling in patients with recurrent renal stone formation and idiopathic hypercalciuria. APMIS 1989;97:309.
19.
Maierhofer WJ, Gray RW, Cheung HS, Lemann J Jr: Bone resorption stimulated by elevated serum 1,25(OH)2-vitamin D concentrations in healthy men. Kidney Int 1983;24:555–560.
20.
Pocock NA, Eisman JA, Hopper JL, Yeates MG, Sambrook PN, Eberl S: Genetic determinants of bone mass in adults. J Clin Invest 1987;80:706–710.
21.
Farrow S: Allelic variation and the vitamin D receptor. Lancet 1994;343:1242.
22.
Wood RJ, Fleet JC: The genetic of osteoporosis: Vitamin D receptor polymorphisms. Annu Rev Nutr 1998;18:233–258.
23.
Eisman JA: Vitamin D receptor gene alleles and osteoporosis: An affirmative view. J Bone Minor Res 1995;10:1289–1293.
24.
Ferrari S, Rizzoli R, Manen D, Slosman D, Bonjour JP: Vitamin D receptor gene start codon polymorphisms (Fok I) and bone mineral density: Interaction with age, dietary calcium and 3′-end region polymorphisms. J Bone Miner Res 1998;13:925–930.
25.
Krall EA, Parry P, Lichter JB, Dawson-Hughes B: Vitamin D receptor alleles and rates of bone loss: Influences of years since menopause and calcium intake. J Bone Miner Res 1995;10:978–984.
26.
Lazaretti-Castro M, Oliveira MAD, Russo EMK, Vieira JGH: Vitamin D receptor alleles and bone mineral density in a normal premenopausal Brazilian female population. Braz J Med Biol Res 1997;30:929–932.
27.
Morrison NA, Yeoman R, Kelly PJ, Eisman JA: Contribution of trans-acting factor alleles to normal physiological variability: Vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc Natl Acad Sci USA 1992;89:6665–6669.
28.
Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TY, Sambrook PN, Eisman JA: Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284–287.
29.
Spector TD, Keen RW, Arden NK, Morrison NA, Major PJ, Nguyen TV, Kelly PJ, Baker JR, Sambrook PN, Lanchbury JS, Eisman JA: Influence of vitamin D receptor genotype on bone mineral density in postmenopausal women: A twin study in Britain. BMJ 1995;310:1357–1360.
30.
Cooper GS, Umbach DM: Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 1996;11:1841–1849.
31.
Peacock M: Vitamin D receptor gene alleles and osteoporosis: A contrasting view. J Bone Miner Res 1995;10:1294–1297.
32.
Ferrari S, Rizzoli R, Chevalley T, Slosman D, Eisman JA, Bonjour JP: Vitamin D receptor gene polymorphisms and change in lumbar spine bone mineral density. Lancet 1995;435:423–424.
33.
Fleet JC, Harris SS, Wood RJ, Dawson-Hughes B: The BsmI vitamin D receptor restriction fragment length polymorphism (BB) predicts low bone density in premenopausal black and white women. J Bone Miner Res 1995;10:985–990.
34.
Riggs BL, Nguyen TV, Melton LJ III, Morrison NA, O’Fallon WM, Kelly PJ, Egan KS, Sambrook PN, Muhs JM, Eisman JA: The contribution of vitamin D receptor gene alleles to the determination of bone mineral density in normal and osteoporotic women. J Bone Miner Res 1995;10:991–996.
35.
Tokita A, Matsumoto H, Morrison NA, Tawa T, Miura Y, Fukamauchi K, Mittsuhashi N, Irimoto M, Yamamori S, Miura M, Watanabe T, Kuwabara Y, Yabuta K, Eisman JA: Vitamin D receptor alleles, bone mineral density and turnover in premenopausal Japanese women. J Bone Miner Res 1996;11:1003–1109.
36.
Garnero P, Borel O, Sornay-Rendu E, Arlot ME, Delmas PD: Vitamin D receptor gene polymorphisms are not related to bone turnover, rate of bone loss, and bone mass in postmenopausal women: The OFELY study. J Bone Miner Res 1996;11:827–834.
37.
Garnero P, Borel O, Sornay-Rendu E, Delmas PD: Vitamin D receptor gene polymorphism do not predict bone turnover and bone mass in healthy premenopausal women. J Bone Miner Res 1995;10:1283–1288.
38.
Hustmyer FG, Peacock M, Hui S, Johnston CC, Christian J: Bone mineral density in relation to polymorphism at the vitamin D receptor gene locus. J Clin Invest 1994;94:2130–2134.
39.
Lim SK, Park YS, Parks JM, Song YD, Lee EJ, Kim KR, Lee HC, Huh KB: Lack of association between vitamin D receptor genotypes and osteoporosis in Koreans. J Clin Endocrinol Metab 1995;80:3677–3681.
40.
Zmuda JM, Cauley JA, Danielson ME, Wolf RL, Ferrell RE: Vitamin D receptor gene polymorphisms, bone turnover, and rates of bone loss in older African-American women. J Bone Miner Res 1997;12:1446–1452.
41.
Ongphiphadhanakul B, Rajatanavin R, Chanprasertyothin S, Chailurkit L, Piaseu N, Teerarungsikul K, Sirisriro R, Komindr S, Puaviali G: Vitamin receptor gene polymorphism is associated with urinary calcium excretion but not with bone mineral density in postmenopausal women. J Endocrinol Invest 1997:20:592–596.
42.
Willing M, Sowers M, Aron D, Clark MK, Burns T, Bunten C, Crutchfield M, D’Agostino D, Jannausch M: Bone mineral density and its change in white women: Estrogen and vitamin D receptor genotypes and their interaction. J Bone Miner Res 1998;13:695–705.
43.
Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res 1994;9:1137–1141.
44.
Vieira JGH, Nishida SK, Kasamatsu TS, Amarante EC, Kunii IS: Development and clinical application of an immunofluorometric assay for intact parathyroid hormone. Braz J Med Biol Res 1994;27:2379–2382.
45.
Martini LA, Heilberg IP, Cuppari L, Medeiros FAM, Draibe SA, Ajzen H, Schor N: Dietary habits of calcium stone formers. Braz J Med Biol Res 1993;26:805–812.
46.
Heilberg IP, Martini LA, Draibe SA, Ajzen H, Ramos OL, Schor N: Sensitivity to calcium intake in calcium stone forming patients. Nephron 1996;73:145–153.
47.
Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TY, Sambrook PN, Eisman JA: Prediction of bone density from vitamin D receptor alleles. Nature 1997;387:106.
48.
Melton LJ III, Crowson CS, Khosla S, Wilson DM, O’Fallon WM: Fracture risk among patients with urolithiasis: A population-based cohort study. Kidney Int 1998;53:459–464.
49.
Zerwekh JE, Hughes MR, Reed BY, Breslau NA, Heller HJJ, Lemke M, Nasonkin I, Pak CYC: Evidence for normal vitamin D receptor messenger ribonucleic acid and genotype in absorptive hypercalciuria. J Clin Endocrinol Metab 1995;80:2960–2965.
50.
Ruggiero M, Pacini S, Amato M, Aterini S, Chiarugi V: Association between vitamin D receptor gene polymorphism and nephrolithiasis: Miner Electrolyte Metab 1999;25:185–190.
51.
Hauache OM, Lazaretti-Castro M, Andreoni S, Gimeno SGA, Brandão C, Ramalho AC, Kasamatsu TS, Kunii I, Hayashi LF, Dib AS, Vieira JGH: Vitamin D receptor gene polymorphism: Correlation with bone mineral density in a Brazilian population with insulin-dependent diabetes mellitus. Osteoporos Int 1998;8:204–210.
52.
Gomez C, Rodriguez-Rebollar A, Naves ML, Fernandez-Coto T, Diaz-Lopes JB, Torres A, Cannata JB: Effects of the different alleles of vitamin D in bone mass and in other biochemical parameters in people older than 54 years with normal renal function (abstract). J Bone Miner Res 1997;12:S372.
53.
Kiel DP, Myers RH, Cupples LA, Kong XF, Zhu XH, Ordovas J, Schaefer EJ, Felson DT, Rush D, Wilson PWF, Eisman JA, Holick MF: The BsmI vitamin D receptor restriction fragment length polymorphism (bb) influences the effect of calcium intake on bone mineral density. J Bone Miner Res 1997,12:1049–1057.
54.
Dawson-Hughes B, Harris SS, Finneran S: Calcium absorption on high and low calcium intakes in relation to vitamin D receptor genotype. J Clin Endocrinol Metab 1995;80:36757–3661.
55.
Ferrari S, Rizzoli R, Slosman D, Bonjour JP: Do dietary calcium and age explain the controversy surrounding the relationship between bone mineral density and vitamin D receptor gene polymorphisms? J Bone Miner Res 1998;13:363–370.
56.
Cole DEC, Trang HM, Vieth R, Peltekova VD, Pierratos A, Wong BYL, Rubin A, Hendy GN: Calcium excretion is independently associated with the vitamin D receptor (VDR) and calcium-sensing receptor (CaSR) polymorphisms in a nephrolithiasis population (abstract). J Bone Miner Res 1998;23(suppl):S248.
57.
Pacifici R, Rothstein M, Rifas L, Lau KW, Baylink DJ, Avioli LV, Hruska K: Increased monocyte interleukin-1 activity and decreased vertebral bone density in patients with fasting idiopathic hypercalciuria. J Clin Endocrinol Metab 1991;71:138–145.
58.
Weisinger JR, Alonzo E, Bellorín-Font E, Blasini AM, Rodriguez MA, Paz-Martínez V, Martins R: Possible role of cytokines on the bone mineral loss in idiopathic hypercalciuria. Kidney Int 1996;49:244–250.
59.
Coe FL, Parks JH, Moore ES: Familial idiopathic hypercalciuria. N Engl J Med 1979;300:503–508.
60.
Pak CYC, McGuire J, Peterson R, Britton F, Harrod MJ: Familial absorptive hypercalciuria in a large kindred. J Urol 1981;126:717–719.
61.
Favus MJ: Familial forms of hypercalciuria. J Urol 1989;141:719–722.
© 2002 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.